Glucose is a major biological fuel in a variety of cells. Yet, due to its water-soluble, polar nature, glucose does not readily cross the lipid bilayer of cell membranes. Thus, all cells that rely on glucose for their metabolism must have a mechanism for facilitating its entry. Under most conditions, glu cose is the principal metabolic fuel for the brain (Siesj6, 1978) . Physiologic mechanisms must there fore ensure an adequate and uninterrupted glucose supply to support the large metabolic needs of the brain. Also, the brain is isolated from the systemic circulation by the blood-brain barrier (BBB), which is composed of capillary endothelial cells joined by tight junctions. Thus glucose must pass through ad ditional membranes to reach neurons and glia.
Unlike that of skeletal muscle, brain glucose me tabolism is phosphorylation-limited rather than transport-limited (Robinson and Rapoport, 1986; Furler et al. 1991) . Even when transport may be come limiting, as in hypoglycemia or in hypermet abolic states, this limitation is at the BBB not at neuronal and glial membranes. All evidence indi cates that glucose is rapidly transported from the cerebral extracellular to the intracellular compart ments (review by Lund-Andersen, 1979) . In brain slices, where no BBB exists, glucose uptake from medium to slice was nearly instantaneous (Lund Andersen, 1979) . Also, the intracerebral distribu tion of the nonmetabolized glucose analogue, 3-0methylglucose, following intravenous administra tion in rats was much greater than the brain extracellular fluid space (Gjedde and Diemer, 1983) .
The BBB glucose transport system was first con sidered by Crone (1963 Crone ( , 1965 and its physiologic properties further characterized in subsequent re ports (e.g. , Buschiazzo et al., 1970; Betz et al., 1973; Pardridge and Oldendorf, 1975; Cremer et al., 1979; Lund-Andersen, 1979; Gjedde, 1983; Par dridge, 1983) . It is now generally accepted that glu cose enters the brain via a carrier-mediated, facili tated diffusion process which is nonconcentrative; not energy dependent; stereospecific (transports D but not L-glucose); Na + -and insulin-independent; inhibitable by phloretin, phlorizin, and the fungal metabolite cytochalasin B (CB); and displays satu ration kinetics and transport competition among hexoses.
Five glucose transporters (GTs), designated GLUT-l to GLUT-5, have been identified to date (Kahn and Flier, 1990; Thorens et al., 1990; Silver man, 1991) . GLUT-l attains its highest expression in brain capillaries (i. e. , the BBB), human erythro cytes, and placenta. It is a 492-amino acid cell membrane glycoprotein with multiple membrane spanning domains (Mueckler et al., 1985; Birnbaum et al. , 1986) . GLUT-l eDNA clones originally were isolated from a human hepatoma (HepG2) cell line (Mueckler et aI., 1985) and rat brain (Birnbaum et al., 1986) . GLUT-3, originally cloned from fetal skeletal muscle, is found in many tissues including the brain. The remaining GTs are not expressed in the brain.
Consistent with the prediction of Crone (1963 Crone ( , 1965 , and because brain endothelium constitutes less than 0. 1% of total brain weight, it would be reasonable to expect that brain microvessels are en dowed with a high density of GT . Dick et al. (1984) identified and characterized the GT of isolated brain microvessels of the rat and pig by CB binding, and established its immunoreactivity to antibodies raised to the erythroid GT, i.e, GLUT-I. Subse quent reports confirmed these observations in a number of adult mammalian species including hu mans (Baldwin et aI., 1985; Dick and Harik, 1986; Kasanicki et aI., 1987; Kalaria et aI., 1988; Par dridge et aI., 1990a) . Also, the mRNA for GLUT-1 was abundant in isolated brain microvessels (Flier et aI., 1987; Weiler-GuttIer et aI., 1989) . More re cently, in situ immunocytochemical techniques confirmed the localization of GLUT-1 in brain en dothelium (Kalaria et aI., 1988; Bagley et aI ., 1989; Kasanicki et aI., 1989; Harik et aI., 1990a) . A high density of GLUT-1 was seen in most brain capillar ies, arterioles, and venules, but not in vessels of circumventricular organs, where BBB characteris tics are lacking (Harik et aI., 1990a; Young and Wang, 1990) . In the choroid plexus, the blood ves sels did not stain, but the choroid epithelium stained intensely.
The subcellular distribution of GLUT-l remains unsettled. Gerhart et aI. (1989) reported that more than 90% of dog brain endothelial GT was equally distributed between luminal and abluminal plasma membranes. On the other hand, Farrell and Par dridge (1991) showed unequal GT distribution in rat brain endothelium, favoring the abluminal mem brane by a margin of four to one. They also reported that 40% of the brain endothelial GT was intracel lular . Dermietzel and Krause (199 1) reported that in the rat brain endothelium 50% of the GT was at the abluminal membrane, 36% at the luminal mem brane, and the rest intracellular.
Immunocytochemistry at both the light micro scopic (Kalaria et aI., 1988; Harik et aI ., 1990a) and ultrastructural levels (Gerhart et aI., 1989; Farrell and Pardridge, 199 1) failed to show appreciable GLUT-l in adult mammalian brain, except in en dothelium, choroid plexus epithelium, and tany cytes (Harik et aI., 1990a; Young and Wang, 1990) . However, GLUT-l immunoreactivity exists in fetal and neonatal brain cells (Devaskar et aI., 199 1; Harik et aI., 1992) . The evidence supporting a pres ence of GLUT-l in adult brain neurons and glia is more limited. Devaskar et aI. (199 1) reported GLUT-l immunoreactivity in adult perivascular as trocytes and Bagley et aI. (1989) found occasional immunostaining in the neuropil. GLUT -1 expres sion was also observed in cultured cells derived from neural tissue (Walker et aI., 1988; Werner et J Cereb Blood Flow Me/ab, Vol. 12, No.6, 1992 aI., 1989 Sadiq et aI ., 1990; Masters et aI., 1991) , but these findings do not reflect the situation in the adult brain . Glucose transport into neurons of the adult brain appears to be subserved by GLUT-3 (Ka yano et aI ., 1988; Sadiq et aI ., 1990; Yano et aI., 199 1; Gerhart et aI., 1992; Maher et aI., 1992; Na gamatsu et aI ., 1992) .
The BBB GT can be modulated by physiologic and pathophysiologic factors. The rate of BBB glu cose influx, or more precisely the maximum trans port velocity (T max) , decreases during cerebral glu cose hypometabolism (Gjedde and Rasmussen, 1980; Hargreaves et aI., 1986) and increases during glucose hypermetabolism (Cremer et aI., 1983; Cre mer et al ., 1988) . Also, there is a good correlation between the relative T max and CMR g \c in different brain structures (Hawkins et aI ., 1983) , In Alzhei mer's disease, a condition associated with dimin ished CMR g \c (Foster et aI ., 1983; Duara et aI ., 1986) , there is a decreased density of GT in cerebral microvessels (Kalaria and Harik, 1989 ) and a dimin ished blood-to-brain glucose influx (Jagust et aI., 199 1) . All these results imply coupling between BBB glucose transport and CMR g \c, but the under lying mechanisms remain unclear.
Increased BBB glucose transport capacity was reported in chronic hypoglycemia (McCall et aI., 1986; Pelligrino et aI ., 1990a) . This response devel oped over several days (McCall et aI., 1986) and was manifested in many brain regions (Pelligrino et aI ., 1990a ). An elevated Tmax was suspected, al though increased transporter affinity (decreased Kt) could not be ruled out.
If BBB glucose transport enhancement occurred in chronic hypoglycemia, it might be expected that the reverse would occur in chronic hyperglycemia. Such down-regulation of BBB glucose transport could "protect" the brain from a hyperosmotic load (Rosen and Andrew, 1991) , alterations of protein/ enzyme functions through glycosylation (Brownlee et aI., 1988) , or factors related to increased sorbitol pathway activity (Greene et aI., 1987) , Repression of BBB glucose transport in chronic hyperglycemia was also suggested as an explanation for the appear ance of hypoglycemic "symptoms" after acute blood glucose normalization in hyperglycemic dia betics (Lilavivathana et aI., 1979; DeFronzo et aI., 1980) . These symptoms were presumed to be a manifestation of cerebral glycopenia at normogly cemia.
In the last decade, a number of studies employing a variety of methodologies examined the issue of BBB glucose transport in hyperglycemia. Some of the studies reported repression (Gjedde and Crone, 1981; McCall et aI., 1982; Matthaei et aI., 1986; Par-dridge et al., 1990b) , others reported no change (Brooks et al., 1986; Duckrow, 1988; Harik and La Manna, 1988) , and still others found evidence sug gesting an enhanced transport Choi et al., 1989; Pelligrino et al. , 1990b) . The ob jective of this review is to evaluate critically the divergent reports. The studies discussed in this section employed the relationships embodied in the Michaelis-Menten and the Kety-Renkin-Crone equations. These are expressed as follows:
(1)
where, Jin is the blood-brain glucose influx rate (/-Lmol g-I min -I ), Ce = the mean cerebral capil lary glucose concentration (/-Lmol ml-I ), T max is the theoretical maximal transport velocity (/-Lmol g-I min -I ), Kt is the plasma glucose concentration at half T max (mM), Kd is the non saturable diffusion coefficient (ml g-I min-I ), PS is the permeability surface area product (ml g-1 min -I ), F p = cerebral plasma flow (ml g-l min -I ), and Cl = the plasma clearance (ml g-I min -I ). Other relationships ex ploited in the analysis of blood-brain glucose trans port include PS = Jin/Ce and CIIF p = extraction (E). At normal and elevated plasma glucose levels, owing to the relatively small drop in glucose con centration when proceeding from the arterial to the venous end of the brain capillary and for the sake of convenience, Ce is often replaced with the arterial plasma glucose concentration (Ca). Alterations in BBB glucose transport generally are considered to occur via changes in T max' Mea surements of E, PS, Jin, and/or Cl in hyperglycemic and control animals can be used to assess T max changes. These variables are sensitive to alterations in plasma glucose levels, and to some degree to changes in cerebral plasma flow and CMR g 1e• Nev ertheless, it is possible to generate curves that de pict the relationships between E, PS, or Jin and Ca, based on established models of BBB glucose trans port and the equations given above. This permits graphic illustration of how changes in T max (and F p ) can influence the position of these curves and rela tionships among the components of Eqs. (1) and (2). W e employed a three-compartment model (plasma, endothelial cell, and brain), that assumes a symmetrical distribution of GTs between the lumi nal and abluminal membranes of endothelial cells. Transport across each membrane was assumed to occur via Michaelis-Menten kinetics. Calculations were based on the two-membrane models described by several investigators (Gjedde and Christensen, 1984; Cunningham et al., 1986; Hargreaves et al., 1986; Oyler and Hawkins, 1986) . Briefly, the mod els described in these reports allowed for alteration of CMR g 1c, F p , and Ca, among other variables, and the luminal and abluminal kinetic constants (the T max for each membrane was double the T max used when treating the BBB as a single membrane). Based on these inputs one can estimate E and Cl; as well as capillary plasma and brain tissue glucose concentrations. PS and Jin could then be calculated from the relationships given above. The Ce value used in the Jin calculation was estimated as Ce = Ca -(CMR g l c12F p ) . The vari ations in E, PS, and Jin with Ca and the influence of T max alterations on these curves are depicted in Figs. 1 and 2. It can be seen that E, PS, and Jin vary with Ca. Thus, it is imperative when measuring and reporting these variables in different groups that Ca is the same in all groups. Furthermore, comparing E between groups is meaningless unless both groups have an identical F p . The rather profound sensitiv ity of E to variations in F p is shown in Fig. 1 (right) .
It should be stressed that the dependence of the PS product on plasma glucose concentration (C p )' combined with a falling C p when progressing from the arterial to the venous end, only permits esti mates of an apparent P S product. What is some times labeled PS is in fact glucose tracer clearance, and Jin is really Cl x Ca (Cunningham and Cremer, 1981; Hawkins et al., 1982; Hawkins et al., 1983; Cremer et al., 1983; Duckrow, 1988; Pelligrino et al. , 1990b) . The accuracy of Cl or Cl x Ca in ap proximating PS or Jin depends on F p . The effect of variations in F p on the ratios of Cl to PS and Cl x Ca to Jin is shown in Fig. 3 . Under normal circum stances, Cl underestimates PS to a modest degree ( Fig. 3, upper portion) . This difference decreases with increasing F p and Ca. The discrepancy be tween Cl x Ca and Jin is less than that for Cl i PS and is not quite as sensitive to variations in Ca or F p ( Fig. 3 , lower portion), mainly because as F p and Ca decrease, the value of Ce relative to Ca also de creases.
Experimental studies
Gjedde and Crone (198 1) were the first to study BBB glucose transport in chronic hyperglycemia. They used streptozotocin (STZ) to induce chronic (3 weeks) hyperglycemia in rats. They estimated D. A. PELL/GRING ET AL. Pla.ma gluCOM (,unol . ml-1 ) c:
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FIG. 1. Variations in cerebral g lucose extraction with chan g es in arterial plasma glucose concentration: effects of increases and decreases in T max for blood-brain g lucose transport (left) or cerebral plasma flow (F p) (right). Curves were g enerated usin g a double-membrane, three compartment model for BBB g lucose transport (Gjedde and Christensen, 1984; Cunnin g ham et aI., 1986; Har g reaves et aI., 1986; Oyler and Hawkins, 1986 ) (see text). Initial values employed in the calculations were: CMRgle = 0.7 fl.mol g -' min-', Fp = 0.6 ml g -' min-1, Tmax = 6 fl.mol g -' min-' (single membrane value), and K, = 8 mM.
glucose transport capacity from measurements of labeled glucose extraction, using an intravenous in jection method in pentobarbital-anesthetized rats while varying Ca over a wide range. area product (PS) for BBB g lucose transfer (top) or the blood-brain g lucose influx rate (J;n) (bottom). The PS versus plasma g lucose curves were g enerated as described in Fi g . 1 and the text, with PS calculated from Eq. 2, where E = C1IF p' For the bottom curves, J;n was calculated from PS = J;n/Ce' where Ce = Ca-(CMRg1J2Fp) (Har g reaves et aI., 1986). Initial values used in the calculations are g iven in the le g end to Fi g . 1.
J Cereb Blood Flow Metab, Vol. 12, No.6, 1992 to be unchanged in chronic hyperglycemia. The variables employed to characterize glucose trans port were Tmax, Kt, and lin, defined as:
cients describing glucose transfer (T max and Kt)
were derived from a direct nonlinear least-squares curve fit of PS versus Ca. No differences in Kt were noted between control and hyperglycemic rats. The
Plasma glucose �mal . ml-1) T max was calculated to be 28% lower in hypergly cemic rats. When comparisons between the two groups were made at a plasma glucose concentra tion of 10 mM , lin was 20% lower in STZ-treated rats. Based on these findings, they concluded that BBB glucose transport was down-regulated in chronic hyperglycemia. The distribution of errors, weighting scheme, and statistical analysis used were not discussed. Given the considerable overlap of individual datum points in the two PS versus Ca curves, the two populations appear indistinguish able. If so, and without any measured differences in F p ' it is unclear how significantly different values for T max (and lin, during euglycemic comparisons) were calculated. The conclusion of Gjedde and Crone (198 1) was supported by a study which compared E values for labeled glucose, 2-deoxyglucose, and 3-0-methyl glucose in hyperglycemic rats (3-11 days post-STZ or alloxan) and controls (McCall et aI., 1982) . Ex traction fractions in the hyperglycemic rats, esti mated by the brain uptake index (BUI) technique under pentobarbital anesthesia, were reduced to 67-89% of control. A similar decrease in the BUI for 3-0-methylglucose in chronically hyperglycemic rats (8 days post-STZ) was recently reported (Moo radian and Morin, 199 1). Assuming unaltered F p , the decreased BUI in chronic hyperglycemia was interpreted as reduced BBB hexose transport. When unlabeled glucose concentrations in the ca rotid injectate were varied from 0 to 80 mM, per mitting the calculation of kinetic variables, the es timated T max was 45% lower in hyperglycemia (Mc Call et aI. , 1982) .
On the other hand, when a labeled glucose intra venous infusion technique was used to estimate re gional brain PS products for glucose transfer in awake rats, there were no significant differences between chronically hyperglycemic (1 and 3 weeks post-STZ) and acutely hyperglycemic rats (Duck row, 1988) . This suggested no change in BBB glu cose transport capacity in chronic hyperglycemia. A similar conclusion was also reached in another study that used the dual tracer, intra-atrial bolus technique (Sage et aI., 198 1; LaManna and Harik, 1985) to measure, simultaneously, E and CBF in different regions of the awake rat brain (Harik and LaManna, 1988) . Analyses of glucose transport changes in acutely hyperglycemic and chronically hyperglycemic (2-5 weeks post-STZ) rats were per formed by comparing lin' The value for lin was de termined according to the relationship lin = -F p X In( 1 -E) X Ca. In the five regions evaluated, no significant differences in lin were observed between chronic and acute hyperglycemia with the excep-tion of a 30% lower lin value in the hippocampus in the 4-5-week hyperglycemic group.
U sing a modification of a double-label 2-deoxy glucose method (Cunningham and Cremer, 1981) , regional BBB glucose lin, glucose utilization, and brain glucose concentrations were compared in normoglycemic control versus STZ-treated (6-8 weeks) rats rendered acutely normoglycemic by in travenous insulin (Pelligrino et aI. , 1990b) . The lat ter group had higher values for CMR g lc, lin, and brain tissue/plasma glucose ratios in most of the brain regions analyzed, implying increased glucose transport in the STZ-treated rats. Also, these re sults did not support the hypothesis (see above) that cerebral glycopenia is responsible for "hypoglyce mic" symptoms when glucose is acutely normalized in human diabetics (see below).
Studies on BBB glucose transport in diabetic hu mans are few. In the one relevant study, BBB glu cose transport was assessed by positron emission tomography in chronically hyperglycemic diabetics with elevated glycohemoglobin levels, treated dia betics, and normal subjects (Brooks et aI., 1986 ). There were no differences in blood-to-brain glucose transport among these groups.
Systemic administration studies are potentially vulnerable to data variability, changes in nonsatura ble diffusion, and inaccuracies in the estimates of PS products or lin' For example, in the study by Duckrow (1988) , decreases in the PS product of up to 17% did not reach statistical significance because of data scatter. Because glucose clearance was ac tually measured (Hawkins et aI., 1982; Hawkins et aI., 1983) , the ability to accurately estimate PS (or PS relationships among hyperglycemic groups) re quired either knowledge of the CBF or assurance that the CBF values were similar in the groups (Fig.  3) . The literature is inconsistent with regard to CBF changes in hyperglycemic rats. Some studies re ported significant decreases (Duckrow et aI. , 1987; Harik and LaManna, 1988; Knudsen et aI., 199 1; Pelligrino and Albrecht, 1991) , some reported no significant changes (Gjedde and Crone, 198 1; Ja kobsen et aI., 1990; Knudsen et aI., 1991) , and at least one study showed CBF increases (Simpson et aI. , 1990) . Nevertheless, as hyperglycemia in creases, the error produced by variations in flow diminishes (Fig. 3) . Taking the extremes for normo glycemic and hyperglycemic CBF values reported in the literature, an error of only �5% would be introduced.
Even in systemic administration studies where blood flow was experimentally determined (when E for D-glucose was taken from the ratio of D-eH]glu cose to r t4 C]butanol in brain tissue divided by the D. A. PELL/GRIND ET AL. same ratio in arterial plasma) a correction had to be applied to the brain 3 H activity for counts derived from plasma contamination of the tissue plus label passing into the brain by simple diffusion (Harik and LaManna, 1988) . This correction may be a source of error because mean values were deter mined in separate experiments using L-[ 3 H]glucose as tracer. The correction ranged from -15% of the total tissue counts in normoglycemic rats to -30% of the total tissue counts in the hyperglycemic groups. The modest differences in the plasma glu cose among the hyperglycemic groups would have little influence on the results (Fig. 2) .
The requirement that lin comparisons be made at the same plasma glucose levels is far more critical in the normoglycemic range than it is in hyperglyce mia (Fig. 2) . In a study where normoglycemic com parisons were performed (Pelligrino et aI. , 1990b) this requirement was met. In that study, lin was actually estimated from Cl x Ca. Based on Fig. 3 (lower portion) and a F p = 0.6 ml g -1 min -1 and Ca = 8 !-Lmol ml-1, Cl x Ca would underestimate the true lin by only -7%. Changes in F p can affect the relationship between Cl x Ca and lin (Fig. 3) . But, in acutely normalized STZ-treated and control rats, F p values were similar (Pelligrino and Albrecht, 1991) , which strengthens the validity of the lin com parisons between these two groups.
The finding of a lin difference during normogly cemic comparisons was bolstered by the additional and more straightforward measurements of higher CMR g l c (Pelligrino et aI., 1990b) and higher tissue/ plasma glucose ratios (Pelligrino et aI., 1990b; Ho fer and Lanier, 1991a; Hofer and Lanier, 1991b) in acutely normalized diabetic rats. The increased CMR g l c coupled with higher than normal tissue/ plasma glucose ratios (in the face of similar F p val ues) is only consistent with increased BBB glucose transport. The reason acutely normalized STZ treated rats show an elevated BBB glucose trans port and chronically hyperglycemic STZ-treated rats do not is, perhaps, because lin comparisons were made at glucose values nearer to the Kt, where the GT would not be saturated. In addition, the in creased lin could be related to the elevated CMR g l c, although the lin change was greater than predicted from studies linking transport and metabolism (Cre mer et aI., 1983; Hargreaves et aI., 1986; Cremer et aI. , 1988) .
Thus, while systemic administration methods showed either no change or increased glucose trans port in chronic hyperglycemia, BUI methods showed decreased glucose transport. The two main factors that affect the interpretation of BUI mea surements are the uncertain concentration of unla-J Cereb Blood Flow Metab. Vol. 12. No.6. 1992 beled substrate in the bolus as it traverses the vas cular bed, and the unknown cerebral perfusion rate during the passage of the tracer bolus.
In BUI studies, the glucose concentration of the injectate was assumed to remain constant during its transit from the injection site in the carotid to the cerebral capillaries, and, except for estimation of kinetic variables, no unlabeled glucose was in cluded in the injectate (McCall et aI., 1982 ; Moora dian and Morin, 1991) . If chronic hyperglycemia were associated with more endogenous glucose competing with radiolabeled glucose in the injec tate, then E during hyperglycemia would appear re duced, as shown in Fig. 4. This figure, reproduced from curves derived by McCall et ai. (1982) , dem onstrates that the effect of contamination is most pronounced in the 0-5-mM glucose concentration range. Likely sources of endogenous glucose that could compete with the tracer in chronic hypergly cemia include: (a) increased brain-to-capillary glu cose efflux due to much higher tissue glucose in hyperglycemia (Betz et aI. , 1973; Ruderman et al., 1974; Duckrow and Bryan, 1987; Mans et aI. , 1988; Hofer and Lanier, 1991a; Hofer and Lanier, 1991b) ; (b) mixing of the bolus with blood prior to reaching the cerebral capillary, an effect that becomes more pronounced in hyperglycemia where the differences between the concentration of glucose in the injec tate and plasma widens; (c) reversible adsorption of glucose to the luminal surface of endothelium ("gly cocalyx binding" ) (Fatehi et aI., 1987; Lucchesi and Gosselin, 1990) . The adsorbed glucose could pro vide a source for competition with labeled glucose. The effect is assumed to be more prominent in hy perglycemia. 
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Unlabeled glucose concentration Uunal • ml-1 ) substrate, using a mathematical model that ac counted for tissue and vascular sources (but not the glycocalyx effect), indicated a maximum potential contribution from these sources of �9% (Pardridge et aI., 1985) . Thus, if no unlabeled glucose is added to the bolus, the glucose content of the carotid in jectate would increase by �2-2.5 mM in the hyper glycemic rats and by �0.5 mM in controls. This could account for less than half of the decrease in E or BUI in the hyperglycemic rats (estimated from the curves in Fig. 4) . However, with the BUI method, there is also uncertainty regarding the pre cise vascular fluid flows during bolus passage. BUI values are dependent on flow (Hardebo and Nils son, 1979) . In addition, local vascular responses to the transient increase in transmural pressure that would accompany bolus passage may be different in hyperglycemic rats . This pressure-induced re sponse appears to be endothelium dependent (Rubanyi et aI., 1990) and cerebral vascular endo thelial function (i.e., flow related) was shown to be impaired during chronic hyperglycemia in rats (Mayhan et aI., 1991; Pelligrino et aI., 1992) . How ever, the effect of such an endothelial pathology on vascular flow responses to intracarotid bolus injec tions has not been assessed experimentally and is not easy to predict. When the glucose transport kinetic variables for normoglycemic and chronically hyperglycemic rats were calculated from data derived by the BUI method using varying amounts of unlabeled glucose in the tracer bolus, a reduction in T max from 1.8 to 1.0 /-Lmol g-I min -I and Kt from 11.5 to 9.1 mM was reported (McCall et aI., 1982) . While there is continuing uncertainty regarding flow and glycoca lyx effects, systematic errors induced by bolus con tamination cannot explain the relative reduction in Tmax' This data provides the strongest evidence for the existence of down-regulation of glucose trans port during chronic hyperglycemia, although it lacks statistical support.
To avoid the flow uncertainties inherent in the BUI method, an in situ internal carotid artery infu sion technique was employed to evaluate BBB glu cose transport in hyperglycemic (6-7 days post S TZ, serum glucose = 25 mM) versus normoglyce mic rats (Pardridge et aI., 1990b) . The method permitted simultaneous estimation of E for glucose and blood flow in the hemisphere ipsilateral to the carotid catheter, and calculation of the glucose PS product. An electrolyte solution (pH 7.4) containing al bumin and labeled diazepam was used as the in fu sate vehicle, which more properly indicates vas cular fluid flow rather than cerebral blood flow. The infu sate also included labeled glucose to calculate glucose clearance. When comparing STZ-treated to normal rats, a 44% lower value for the calculated PS-product was found, but this was due to a con comitant 44% reduction in cerebral vascular fluid flow, because E did not differ. It should be noted that vascular fluid flows in normal rats were much lower than the values reported in the original de scription of this technique (Takasato et aI., 1984) . The low vascular fluid flow values were probablY due to the presence of albumin in the perfusate. Albumin binds to diazepam and reduces its brain uptake (Fenerty and Lindup, 1989) .
The method used by Pardridge et ai. (1990b) was less subject to the effects of infusate contamination by endogenous glucose than in BUl studies. Ac cording to Takasato et ai. (1984) , a 7-8% contami nation would occur at a saline infusion rate of 4 ml min -1 (the rate used by Pardridge et aI ., 1990b) . This would amount to a 1-1.5 mM increase in the infusate glucose concentration of 10 mM in the hy perglycemic rats (plasma glucose = 25 mM) . An other 0.5 mM could be added due to brain efflux contamination (Pardridge et aI ., 1985) . In normogly cemia (plasma glucose = 5.7 mM), only an incon sequential net reduction of infusate glucose might occur. Applying these estimations of infusate glu cose levels changes to the relationship described in Fig . 4 , endogenous glucose contamination effects could not account for more than 10-15% of the re duction in the PS-product in chronic hyperglyce mia. This error would be larger if glucose is released into the infusate from the glycocalyx .
Indirect experimental evidence
Brain glucose content is a function of BBB glu cose transport and CMR g l c (e.g., Cunningham, 1986) . Because BBB glucose transport rate depends on plasma glucose concentration, the brain/plasma glucose ratio can be used as an indicator of BBB glucose transport if CMR g \c is known. Beyond this, it is possible to predict the brain/plasma glucose ratios for given values of CMR g \c, T max' and Kt, F p and Ca, by using the 3 compartment model of BBB glucose transport (Cunningham, 1986; Cunningham et aI., 1986; Oyler and Hawkins, 1986) . Thus, re view of literature values for CMR g \c and brain/ plasma glucose ratios can yield information con cerning glucose transport capacity at the BBB in hyperglycemic states.
In Table 1 is summarized the relevant literature and in Table 2 is estimated the brain/plasma glucose ratios based on a 25% increase, 15% decrease, or no change in CMR g \c from a control value of 0.7 /-Lmol g -1 min -I. These represent the range of reported CMR g \c changes in rats (Table 1) for hyperglycemic durations ranging from 2 days to 6--8 weeks . The tissue/plasma glucose ratios were calculated at a "normal" Tmax, a Tmax reduced by 33%, and a Tmax reduced by 45%. This includes the range of T max decrements reported by Gjedde and Crone (1981) , McCall et al. (1982) , and Pardridge et al. (1990b) . The brain/plasma glucose ratio predictions given in Table 2 were derived using three approaches and assumed steady-state conditions. Methods I (Oyler and Hawkins, 1986 ) and II ("Type I" kinetics, as labeled by Cunningham et al., 1986) are similar in that they consider the luminal and abluminal mem branes as separate entities but with equivalent transport capabilities and where the T max of each membrane is double the T max of the BBB as a whole. Method III, or "Type II" kinetics in the Cunningham et al. (1986) designation, is based on a simple stereospecific pore model, where Kt is the sum of the glucose concentrations on either side of the endothelial membrane when half the channels are occupied. This Kt is 5-6 mM lower than the conventional Kt. The confidence one can apply to the predictions presented in Table 2 is strengthened by the similarity in the values derived by the three methods. In addition, we can also employ methods I-III to predict T max changes for given (and mea sl1red) variations in CMR g l C and the brain/plasma glucose ratio. Although not listed in Table 2 , such "predicted" T max changes are discussed in the fol lowing paragraphs. The references listed in Table 1 are arranged by increasing hyperglycemic duration. Note that the studies of McCall et al. (1982) , Pardridge et al.
(1 990b), and Mooradian and Morin (1991) fall into the shorter durations (<s8 days). These studies are not listed in Table 1 because no measurements of brain glucose or CMR g lc were made. In the two re ports where CMR g lc was measured at <s8 days post STZ, a significant increase to 125% of control was found (Mans et al., 1988; Jakobsen et al., 1990) . This, according to the predictions given in Table 2 , should result in a decrease in the brain/plasma glu cose ratio to 75-77% of control, if Tmax remains unchanged, and a decrease in the ratio to 19-27% of control, if Tmax is reduced by 45%. However, in four out of the five reports where brain/plasma ra tios were obtained at <s8 days of hyperglycemia, there was a 15-50% increase over control. In the a See Table 1 . The calculations employed either the Oyler and Hawkins (1986) program (Method I), or the equations provided by Cunningham et al. (1986) for "Type I" (Method II) or "Type II" kinetics (Method III). For methods I and II, we used Kt = 8 mM, single membrane Tmax = 6 fLmol g-I min-I . For Method III, the baseline Tmax (3.2 fLmol g-1 min-I ) and K, (1.7 mM) were taken from the regional averages of the data published by Cunningham et al. (1986) . We assumed a cerebral plasma flow = 0.6 ml g-1 min -1 in normoglycemia and 0.5 ml g-I min-1 in hyperglycemia.
b Numbers in parentheses are b/p glucose values expressed as percent hyperglycemic baseline (row 2) values.
one exception (Mans et aI., 1988) , the decreased brain/plasma ratio translates to only a 10-13% re duction in BBB glucose transport T max' using the CMRglc increase of 25% measured in the same study. On the other hand, in the 3-4-week hyper glycemic rats of the same study (Mans et aI. , 1988) , an increase in the ratio to 116% of control was re ported, along with a normal CMRglc • According to the models employed to generate Table 2 , this is consistent with a �20% increase in T max ' In the three shorter-term studies in which no CMRglc changes are listed in Table 1 , the average 27% elevation in the brain/plasma glucose ratio cal culates to �70% increase in T max ' if accompanied by a 25% elevation in CMRglc • With a 13% decrease in CMRglc (the average from the regional values re ported by Duckrow and Bryan, 1987) there is still a calculated 12-13% increase in T max ' The other stud ies cited in Table 1 (Duckrow and Bryan, 1987; Pel ligrino et aI., 1990b) , predict little or no change in T max from control.
In conclusion, analysis of the literature reporting brain/plasma glucose ratios and CMRglc changes in rats with chronic hyperglycemia provides no sup port for a repression of BBB glucose transport, and actually appears to favor an increase.
INVESTIGATIONS OF THE EFFECTS OF

HYPERGLYCEMIA ON THE GLUCOSE
TRANSPORTER OF ISOLATED
CEREBRAL MICROVESSELS
In these studies, hyperglycemic conditions were imposed in vivo and assays for the GT, whether by CB binding or by GLUT-l immunoreactivity, or in ferred from GLUT-l mRNA determinations were all performed in isolated cerebral microvessels.
Cytochalasin B binding assays
There are three studies where D-glucose-dis placeable CB binding was evaluated in cerebral mi crovessels harvested from chronically hyperglyce mic rats (1-4 weeks post-STZ). The results are con flicting. In one study, a 38-50% decrease in maxi mal CB binding sites was measured in several subcellular fractions of microvessels (Matthaei et aI. , 1986) . It was concluded that in chronically hy perglycemic rats, perhaps via the associated insulin deficiency, there is a reduction in GT density at the BBB. On the other hand, a subsequent study found a 30% increase in the maximal CB binding sites in total particulate fractions of cerebral microvessels isolated from hyperglycemic rats, indicating up regulation of GT at the BBB (Harik et aI., 1988) . To further complicate this issue, a third investigation measured no significant differences in the density of specific CB binding sites in brain microvessels iso lated from STZ-treated and control rats (Mooradian and Morin, 1991) .
A concern with the Matthaei et ai. (1986) report is that the maximal CB binding values, even in con trois, ranged from 17 pmol mg -1 protein in plasma membranes to 31 pmol mg -1 protein in high-density microsomes, which are much lower than most liter ature values (Table 3) . The low CB binding results could have been caused by tissue sonication prior to CB binding. Sonication is known to decrease mark edly specific CB binding (Harik et aI., 1988) . We   TABLE 3 . Summary of published CB-binding results in brain microvessels Reference Species; type of microvessel preparation Unless otherwise stated, the type of microvessel preparation is total particulate fraction. All microvessels were obtained from adults. a Bound and unbound ligands were separated by filtration. b Cytochalasin B binding was performed by equilibrium dialysis. C Bound and unbound ligands were separated by centrifugation. d Tissues were obtained at autopsy after a 3-15-h postmortem delay. cannot explain the discrepancy between the nega tive results of Mooradian and Morin (1991) and the positive findings of . Resolution of these problems must await further studies and the development of more sensitive and specific as say procedures. Two statements of caution are in order. First, although CB binding is a good method for GT quantitation, especially in isolated cerebral microvessels where GT density is high, it is not specific for GLUT-l because CB binds specifically to a number of facilitative GTs. Second, a change in GT density in brain microvessels does not neces sarily mean a corresponding change in glucose transport at the BBB. The GT density is a static value, whereas glucose transport is a dynamic rate. Furthermore, not all GTs that bind CB may be func tional; at least a portion of them may be located in intracellular organelles.
Messenger RNA Evaluations
Increased GLUT-l mRNA levels in isolated brain microvessels from diabetic rats (6 days post-STZ) were reported (Choi et a!., 1989) . Inasmuch as the increased mRNA levels imply increased GLUT-1 synthesis, this finding is consistent with increased CB binding in cerebral microvessels of STZ-treated rats (Harik et a1., 1988) . Curiously, Choi et a1. (1989) explained their findings as an example of fail ure of translation in protein synthesis, as they were convinced that repression of BBB glucose transport in chronic hyperglycemia was an established fact.
Immunoblot assay
In a recent study using quantitative immunoblot ting, a decrease, to 23% of control, in brain mi crovessel GT density in STZ-treated rats (6-7 days) was reported (Pardridge et aI., 1990b) . These au thors calibrated their assay with purified GT from human erythrocytes, but the isolated brain mi crovessels were dissolved in sodium dodecylsulfate prior to immunoblotting, which might alter anti genic properties of proteins (Harlow and Lane, 1988) . This, of course, does not explain the reported differences between control and STZ-treated rats, unless the GT in cerebral microvessels of STZ treated rats is more sensitive to detergents.
Interestingly, in a study from the same laboratory and in similar preparations, isolated cerebral mi crovessels from control rats had a GT density of about 12 pmol mg-l protein when assayed by quan titative immunoblotting or by CB binding (Par dridge et a!., 1990a). This density of GTs, which is even lower than that reported by Matthaei et a!. (1986) , contrasts markedly with the severalfold higher values reported for a variety of mammalian species (Table 3) . Immunological assays for J Cereb Blood Flow Metab, Vol. 12, No.6, 1992 GLUT-l in brain microvessels should be more spe cific than CB binding. However, if GLUT-l is the only GT in brain microvessels, as the evidence to date suggests, the greater sensitivity of the CB bind ing assay should render this technique at least as effective as immunoblotting in assessing GLUT-l levels. Further studies are needed to reconcile the low density of GTs in cerebral microvessels re ported by Pardridge et al. (1990a ) (and Matthaei et a!., 1986 with the higher values from other labora tories. The equally low results obtained by quanti tative immunoblotting in the same preparations of brain microvessels by Pardridge et a1. (1990a) also calls into question the reliability of GLUT-l immu noblotting measurements.
Pardridge et a!. (I 990b ) reconciled the decreased GT immunoreactivity in brain microvessels of STZ treated rats with the increased mRNA levels under the same conditions (Choi et a!., 1989) by proposing inhibition of BBB GLUT-1 translation or increased GT degradation, Further investigations are clearly warranted,
HYPERGLYCEMIA AND GLUCOSE TRANSPORT IN NON-BBB TISSUES
There is a large body of literature, both in vivo and in vitro, assessing glucose transport modifica tions in a variety of tissues in the face of variations in glucose concentration, A comprehensive account of this literature is beyond the scope of this review. Because GLUT-l is the predominant BBB trans porter, examples from tissues with a similar pre dominance of GLUT-1 will be cited.
Harik et a1. (199 1) reported a significant increase in CB binding in erythrocyte membranes of diabetic subjects. This was associated with a higher density of binding sites, but without a significant change in binding affinity, CB binding to erythrocyte mem branes correlated positively with both erythrocyte glycohemoglobin and serum glucose levels but not with plasma C-peptides. Consistent with this, Bis tritzer et a1. (1991) found a significantly higher rate of 3-0-methyl-D-glucose uptake into erythrocytes of diabetic subjects. Similar results were reported by Okuno et a1. (1991) , who measured insulin insensitive 3-0-methyl-D-glucose uptake in poly morphonuclear leukocytes from subjects with un treated diabetes mellitus. These data are all com patible with up-regulation of GLUT-l in chronic hyperglycemia.
The GLUT-l transporter was shown to be highly concentrated in various blood-ocular barrier struc tures including the retinal microvascular endothe-lium, retinal pigment epithelium, and ciliary body epithelium (Harik et at ., 1990b; Takata et at., 1990) . Studies on blood-()cular glucose transport in chron ically hyperglycemic rats produced conflicting re sults. DiMattio et at . (1981) found no change in fa cilitated labeled D-glucose transport at the retinal pigment and ciliary epithelia in STZ-treated (-5 months) rats, although passive glucose transport (labeled L-glucose passage) was increased. Con versely, Ennis et at . (1982) , using a procedure that monitored glucose transport at the retinal microvas cular endothelium and pigment epithelium, reported a reduced retinal extraction for glucose in STZ treated (2 months) rats that they attributed to a large increase in the glucose transport Kt.
CONCLUDING REMARKS
Initial studies of BBB glucose transport in chron ically hyperglycemic rats concluded a diminished transport capacity (Gjedde and Crone, 198 1; Mc Call et at., 1982) . Thus, the concept that down regulation of glucose transport occurs during chronic hyperglycemia often has been accepted as fact. More recent studies indicate that such a con clusion was premature. Indeed, we think that the evidence is stronger in supporting no alteration in glucose transport in chronic hyperglycemia, and perhaps even an increase. Transport repression is supported mainly by those studies using intracarot id tracer administration which, methodologically, are associated with more uncertainty and potential error than studies using systemic tracer administra tion. Nevertheless, until the components of the BBB glucose transporter system (e.g., GT synthesis and activation, blood flow) are understood, it will be difficult to resolve these differences. In vitro studies also yielded controversial results. Reports of down-regulation of BBB GT during hyperglyce mia derive from GT density measurements that even in control cerebral microvessels gave values that were far lower than those usually reported.
